Free tool
Oncology stocks
We cover 120 companies grouped under the Oncology theme. The median market value in the group is $470.55M. Across the group, the median move over the past trading day is +1.42%. 59% of the 115 with a 200-day average trade above it. Price change over the past year runs from −31.2% to +267.8% across the middle 80 percent of the group, with a median of +26.7%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
120 of 319 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| 6MK.DE | Merck & Co., Inc. | 129.28 EUR | +11.62% | +44.70% | +83.96% |
| MRK | Merck & Co., Inc. | $156.45 | +19.65% | +48.06% | +88.17% |
| AZN.L | AstraZeneca PLC | 12,110.00 GBP | −6.41% | −10.89% | +1.98% |
| AZN | AstraZeneca PLC | $169.66 | +0.01% | −6.39% | +7.60% |
| A1ZN34.SA | AstraZeneca PLC | 144.34 BRL | +0.85% | −12.75% | +1.51% |
| ZYME | Zymeworks Inc. | $27.47 | +19.43% | +3.19% | +88.54% |
| IMCR | Immunocore Holdings plc | $37.40 | +10.75% | +10.72% | +14.76% |
| DMRA | Damora Therapeutics, Inc. | $30.62 | +4.01% | +40.33% | +800.59% |
| GXE.DE | Lakefront Biotherapeutics NV | 24.68 EUR | +0.41% | −12.36% | −44.50% |
| VIR | Vir Biotechnology, Inc. | $10.71 | +21.70% | +80.30% | +144.52% |
| INBX | Inhibrx Biosciences, Inc. | $122.72 | +48.84% | +63.54% | +390.10% |
| SNDX | Syndax Pharmaceuticals, Inc. | $19.92 | −2.92% | −6.48% | +27.20% |
| BCAX | Bicara Therapeutics Inc. | $24.58 | −11.61% | +50.06% | +117.14% |
| AAPG | Ascentage Pharma Group Internat | $16.79 | −11.12% | −36.33% | −61.38% |
| AVBP | ArriVent BioPharma, Inc. | $31.35 | +3.95% | +50.72% | +62.02% |
| REPL | Replimune Group, Inc. | $15.80 | +83.08% | +77.53% | +187.80% |
| AKTS | Aktis Oncology, Inc. | $26.69 | +10.24% | +19.15% | +19.15% |
| CGEM | Cullinan Therapeutics, Inc. | $22.95 | +31.67% | +126.78% | +200.39% |
| ORIC | ORIC Pharmaceuticals, Inc. | $13.83 | +15.06% | +69.28% | +43.76% |
| DRTS | Alpha Tau Medical Ltd. | $14.70 | +20.39% | +204.35% | +357.94% |
| IMTX | Immatics N.V. | $9.24 | +7.07% | −11.58% | +76.67% |
| GLUE | Monte Rosa Therapeutics, Inc. | $14.56 | −35.46% | −4.90% | +217.21% |
| CRVS | Corvus Pharmaceuticals, Inc. | $14.56 | +12.69% | +98.91% | +167.16% |
| 0HFQ.L | AnaptysBio, Inc. | $56.87 | −3.20% | +24.44% | +183.92% |
| 2160.T | GNI Group Ltd. | 2,765.00 JPY | +12.58% | +20.74% | +4.54% |
| JANX | Janux Therapeutics, Inc. | $18.68 | +19.97% | +36.85% | −18.82% |
| PHIL.MI | Philogen S.p.A. | 23.35 EUR | −2.71% | +3.88% | +2.12% |
| KURA | Kura Oncology, Inc. | $13.59 | +33.89% | +31.49% | +77.65% |
| CADL | Candel Therapeutics, Inc. | $13.60 | +36.55% | +150.00% | +138.18% |
| GERN | Geron Corporation | $1.55 | +4.73% | +17.42% | +9.15% |
| EUZ.DE | Eckert & Ziegler SE | 13.65 EUR | −0.29% | −9.06% | −23.06% |
| OLMA | Olema Pharmaceuticals, Inc. | $10.91 | −9.16% | −56.84% | +95.17% |
| 4587.T | PeptiDream Inc. | 1,135.00 JPY | +22.00% | −29.98% | −28.26% |
| ANL | Adlai Nortye Ltd. | $13.74 | +13.93% | +895.65% | +737.80% |
| RIGL | Rigel Pharmaceuticals, Inc. | $46.75 | +25.03% | +11.76% | +14.75% |
| AURA | Aura Biosciences, Inc. | $7.82 | +9.22% | +47.55% | +19.94% |
| NVCT | Nuvectis Pharma, Inc. | $25.89 | +32.50% | +204.23% | +298.92% |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $9.37 | +7.09% | −23.76% | −3.50% |
| MNPR | Monopar Therapeutics Inc. | $110.82 | +0.44% | +67.88% | +264.30% |
| CTMX | CytomX Therapeutics, Inc. | $3.37 | +3.69% | −20.71% | +68.50% |
| 4588.T | Oncolys BioPharma Inc. | 4,130.00 JPY | +65.80% | +176.44% | +526.71% |
| 0SZI.L | Corbus Pharmaceuticals Holdings, Inc. | $11.16 | +4.01% | +42.04% | +5.13% |
| GUD.TO | Knight Therapeutics Inc. | 9.75 CAD | −0.71% | +64.97% | +49.08% |
| EIKN | Eikon Therapeutics, Inc. | $12.55 | +27.02% | −16.33% | −16.33% |
| 0QAV.L | Nanobiotix S.A. | 34.51 EUR | −2.83% | +80.19% | +346.30% |
| CU6.AX | Clarity Pharmaceuticals Ltd | 2.48 AUD | +16.98% | −33.15% | −27.91% |
| VSTM | Verastem, Inc. | $7.08 | +16.45% | −2.07% | −21.16% |
| SGMT | Sagimet Biosciences Inc. | $10.29 | +38.12% | +71.79% | +45.34% |
| CBIO | Crescent Biopharma, Inc. | $17.00 | +0.41% | +53.43% | +15.65% |
| ARVN | Arvinas, Inc. | $9.60 | +16.79% | −16.30% | +28.34% |
| DCTH | Delcath Systems, Inc. | $16.92 | +41.71% | +70.05% | +55.37% |
| 0KCS.L | OPKO Health, Inc. | $1.51 | +2.03% | +16.20% | +5.63% |
| PRLD | Prelude Therapeutics Incorporated | $6.59 | +69.41% | +141.39% | +418.90% |
| CCCC | C4 Therapeutics, Inc. | $4.20 | +16.99% | +117.62% | +66.01% |
| TOI | Starling Oncology Inc | $6.20 | +19.46% | +68.94% | +78.67% |
| 0IL8.L | Kyntra Bio, Inc. | $7.95 | +1.50% | −11.24% | −24.41% |
| J8J.F | TransThera Sciences (Nanjing), Inc. | 1.02 EUR | −0.97% | −91.09% | −91.09% |
| RLMD | Relmada Therapeutics, Inc. | $4.59 | −11.73% | +5.03% | +635.58% |
| ALVIO.PA | Valerio Therapeutics Société anonyme | 0.79 EUR | +5.76% | +374.47% | +1150.00% |
| PBYI | Puma Biotechnology, Inc. | $9.32 | +16.65% | +61.53% | +86.77% |
| 0LOV.L | Verastem, Inc. | $7.14 | +3.48% | −1.92% | −21.47% |
| CMPX | Compass Therapeutics, Inc. | $2.53 | +21.63% | −51.06% | −16.23% |
| AVCT.L | Avacta Group Plc | 68.80 GBP | +0.44% | +19.65% | +32.31% |
| FENC | Fennec Pharmaceuticals Inc. | $11.71 | +14.69% | +52.47% | +35.38% |
| FHTX | Foghorn Therapeutics Inc. | $6.85 | +31.73% | +31.98% | +30.48% |
| PRTC.L | PureTech Health plc | 118.80 GBP | +0.51% | −4.65% | −11.34% |
| GALT | Galectin Therapeutics Inc. | $3.99 | +18.05% | −1.48% | −0.25% |
| FRX.TO | Fennec Pharmaceuticals Inc. | 15.49 CAD | +5.73% | +48.80% | +27.38% |
| AGEN | Agenus Inc. | $8.36 | +36.38% | +158.82% | +90.43% |
| CATX | Perspective Therapeutics, Inc. | $3.29 | +16.67% | +17.92% | −4.91% |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $3.88 | −13.97% | +183.21% | +113.19% |
| STRO | Sutro Biopharma, Inc. | $21.44 | −10.70% | +95.62% | +155.24% |
| 0XOD.L | UroGen Pharma Ltd. | $46.35 | −1.31% | +105.18% | +136.32% |
| IMRX | Immuneering Corporation | $5.23 | +19.95% | −21.00% | −12.10% |
| BCYC | Bicycle Therapeutics plc | $4.39 | +11.14% | −34.28% | −38.34% |
| RAC.AX | Racura Oncology Ltd | 2.15 AUD | +5.39% | −25.09% | +72.00% |
| WHWK | Whitehawk Therapeutics, Inc. | $5.08 | +37.30% | +108.20% | +198.82% |
| ALXO | ALX Oncology Holdings Inc. | $2.00 | −0.99% | +73.91% | +81.82% |
| CGEN | Compugen Ltd. | $2.87 | +20.59% | +85.16% | +100.70% |
| MGNX | MacroGenics, Inc. Common Stock | $4.17 | +4.25% | +159.01% | +154.27% |
| TNG.PA | Transgene SA | 0.81 EUR | +12.40% | −15.23% | −16.98% |
| GLSI | Greenwich LifeSciences, Inc. | $18.59 | +38.32% | −4.52% | +56.35% |
| 0IV3.L | Geron Corporation | $1.54 | 0.00% | +16.67% | +8.41% |
| PYXS | Pyxis Oncology, Inc. | $3.06 | +5.15% | +166.09% | +120.14% |
| IPHA | Innate Pharma S.A. | $2.27 | +28.10% | +24.73% | +1.34% |
| SPL.AX | Starpharma Holdings Limited | 0.74 AUD | −1.34% | +101.37% | +465.38% |
| ADAG | Adagene Inc. | $3.82 | +8.22% | +107.61% | +62.55% |
| IDD.DE | Innate Pharma S.A. | 1.78 EUR | +12.80% | +12.80% | −2.52% |
| IPH.PA | Innate Pharma S.A. | 1.88 EUR | +17.37% | +16.21% | +1.84% |
| TARA | Protara Therapeutics, Inc. | $3.97 | −1.73% | −26.21% | +30.16% |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $11.31 | +24.56% | +43.71% | +14.36% |
| NBP | NovaBridge Biosciences | $1.93 | +8.43% | −54.80% | −59.96% |
| CHRS | Coherus Oncology, Inc. | $1.37 | −6.16% | 0.00% | +17.09% |
| BINV.ST | BioInvent International AB (publ) | 24.30 SEK | +4.07% | −17.21% | −24.30% |
| MENS | Jyong Biotech Ltd. | $2.23 | −8.23% | −34.60% | −95.26% |
| CUE | Cue Biopharma, Inc. | $26.76 | −17.84% | +164.69% | +9.05% |
| MOLN | Molecular Partners AG | $4.38 | +9.36% | +3.79% | +3.91% |
| KZIA | Kazia Therapeutics Limited | $13.79 | +12.94% | +175.80% | +83.87% |
| OKUR | OnKure Therapeutics, Inc. | $3.85 | −4.94% | +30.07% | +36.77% |
| ASRT | Assertio Holdings Inc | $23.50 | 0.00% | +157.11% | +98.31% |
| INDP | Indaptus Therapeutics, Inc. | $1.10 | −46.32% | −60.04% | −84.51% |
| 0IMT.L | Photocure ASA | 53.80 NOK | +0.35% | −25.59% | −12.59% |
| HPHA.DE | Heidelberg Pharma AG | 2.53 EUR | −1.17% | +1.20% | −44.40% |
| SCLP.L | Scancell Holdings plc | 9.80 GBP | −1.51% | −1.01% | −6.67% |
| ADCT | ADC Therapeutics SA | $1.04 | −8.77% | −70.45% | −66.34% |
| HURA | TuHURA Biosciences, Inc. | $2.04 | −7.69% | +172.00% | −30.85% |
| 0RU5.L | Oncoinvent ASA | 70.20 NOK | −18.37% | +61.75% | +5951.72% |
| CTX.WA | Captor Therapeutics Spolka Akcyjna | 72.40 PLN | −2.95% | −3.47% | +76.16% |
| LIXT | Nomad Power Solutions Inc | $4.15 | −6.74% | +8.07% | +26.14% |
| BDTX | Black Diamond Therapeutics, Inc. | $2.24 | +29.48% | −10.04% | −21.95% |
| ANIX | Anixa Biosciences, Inc. | $3.66 | +5.78% | +15.82% | +22.00% |
| GNLX | Genelux Corporation | $2.72 | −7.80% | −40.22% | −27.27% |
| NTHI | NeOnc Technologies Holdings, Inc. | $4.71 | +36.92% | −46.96% | −18.72% |
| 0RDB.L | Oryzon Genomics S.A. | 2.84 EUR | +0.92% | −11.03% | +4.08% |
| RVU.WA | Ryvu Therapeutics S.A. | 18.80 PLN | +25.33% | −30.76% | −34.72% |
| 4889.T | Renascience Inc. | 1,378.00 JPY | −7.70% | −3.57% | −37.68% |
| FARN.L | Faron Pharmaceuticals Oy | 41.00 GBP | −4.65% | −78.97% | −80.71% |
| HBP.TO | Helix BioPharma Corp. | 1.99 CAD | +38.19% | −17.08% | +35.37% |
| ONCY | Oncolytics Biotech Inc. | $0.86 | +7.68% | −12.10% | −12.99% |
| AMAN | Amanat Acquisition Corp | $10.69 | +5.32% | +6.79% | +6.79% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.